Modeling Alzheimer's risk using human TREM2-knockout microglia

Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease. Based on the 2020 Nature Communications paper "Gene Expression and Functional Deficits Underlie TREM2-Knockout Microglia Responses in Human Models of Alzheimer’s Disease"
Publish Date: February 11, 2021 Views: 284

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.